EMP-123

**EMP-123** is an investigational allergen-specific immunotherapy developed by Allertein for peanut allergy. It is a rectally administered suspension containing recombinant modified forms of the major peanut allergens Ara h 1, Ara h 2, and Ara h 3, with amino-acid substitutions intended to reduce IgE-binding, encapsulated in heat/phenol-killed *Escherichia coli*. In a completed Phase 1 study, rectal dose escalation produced frequent allergic reactions among peanut-allergic participants, including anaphylaxis; the program has not advanced beyond Phase 1 in identified public sources.

Other names

e. coli-encapsulated, recombinant modified peanut proteins ara h 1ara h 2and ara h 3